Probiotic agent for reducing fat inflammation and use thereof
By constructing a bacterial antigen complex using Akkermansia amyloliquefaciens AH39 and a specific antigen fragment, the problem of insufficient targeting of existing probiotic preparations to distal adipose tissue has been solved, achieving precise intervention in adipose inflammation and restoration of metabolic balance.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SHANGHAI HELPLIFES TECH CO LTD
- Filing Date
- 2026-05-27
- Publication Date
- 2026-07-17
AI Technical Summary
Current probiotic preparations cannot be precisely targeted and delivered to distal adipose tissue, resulting in limited effectiveness in improving adipose inflammation and a high risk of rebound.
Akkermansia myxophilus AH39 was used as an active carrier to construct a bacterial antigen complex by combining it with specific antigen fragments. The complex intervened in the immune tolerance deficiency mechanism of adipose inflammation through the affinity of the bacterial mucus layer, inducing the body to produce specific immune tolerance and enhancing the delivery of anti-inflammatory substances to distal adipose tissue.
It achieves precise targeted intervention on adipose tissue inflammation, reduces aspartate aminotransferase levels, controls fat accumulation, restores systemic metabolic balance, inhibits the production of pro-inflammatory factors, repairs the intestinal barrier, regulates lipid metabolism in the liver and adipose tissue, relieves endoplasmic reticulum stress in muscles, and maintains muscle synthesis.
Smart Images
Figure CN122399009A_ABST